HK Stock Market Move | XUANZHUBIO-B(02575) increased by nearly 3%. The self-developed innovative drug Xuan Yuening was included in the 2025 National Basic Medical Insurance Catalog for the first time.

XUANZHUBIO-B (02575) rose nearly 3%, as of the time of writing, it had increased by 1.98% to 66.95 Hong Kong dollars, with a turnover of 151.953 million Hong Kong dollars. In terms of news, on December 8th, XUANZHUBIO-B announced that its self-developed innovative drug Pilocycline tablets (trade name: Xuanyue Ning) had been included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List (2025)" (2025 National Basic Medical Insurance Catalog). The 2025 National Basic Medical Insurance Catalog will officially be implemented on January 1, 2026. The outcome of this medical insurance negotiation will help the company further increase the affordability and accessibility of Xuanyue Ning among patients, promote the market expansion of this drug, increase sales, and positively impact the company's long-term business development. The company will actively cooperate to promote the implementation of medical insurance policies, continue to promote hospital access, expand core markets, and increase market coverage in order to continuously improve the accessibility of medication for patients.